Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide vs Velcade in melphalan-refractory multiple myeloma
2007-001292-11Phase 3Completed
- Sponsor
- Nordic Myeloma Study Group
- Start
- May 2007
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Thalidomide arm with Velcade arm (2 arms). Primary endpoint: Progression-free survival. Started May 2007; status: completed.
02
Drugs
thalidomidebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2007-001292-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001292-11.